Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

In the last few years, a great interest has emerged in investigating the pleiotropic effects of
Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs). While GLP-1RAs ability to lower …

Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD),
including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications …

Atherosclerosis is a chronic inflammatory response that increases the risk of cardiovascular
diseases. An in-depth study of the pathogenesis of atherosclerosis is critical for the treatment …

Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown
cardiovascular benefits in cardiovascular outcome trials in type 2 diabetes mellitus …

Diabetes is a worldwide health issue closely associated with cardiovascular events. Given
the pandemic of obesity, the identification of the basic underpinnings of vascular disease is …

Obstructive sleep apnoea (OSA) is a major health concern worldwide and adversely affects
multiple organs and systems. OSA is associated with obesity in> 60% of cases and is …

Background Liraglutide is an antidiabetic agent with cardioprotective effect. The purpose of
this study is to test efficacy of liraglutide to improve diabetic cardiomyopathy in patients with …

Aims It remains unclear which sodium-glucose cotransporter-2 (SGLT-2) inhibitors and
glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are most effective for preventing …

Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and
glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular …